Close

move up move left move right move bottom

Proven Efficacy in Nonvalvular AF

XARELTO® reduced the risk of stroke and non-CNS systemic embolism in the ROCKET AF trial, a randomized, phase 3, multicenter, active-controlled, double-blind, double-dummy, event-driven study in more than 14,000 patients with nonvalvular AF at moderate to high risk for stroke.1 Efficacy in patients with moderate renal impairment was consistent with the overall trial.2

XARELTO® effectively reduces stroke risk

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.